Semax Modifies Immune and Vascular Gene Expression After Rat Brain Stroke
Background
Ischemic stroke, a leading cause of death and long-term disability, occurs when blood flow to the brain is interrupted, leading to neuronal damage. Current treatments are limited, highlighting an urgent need for novel neuroprotective strategies. While the peptide Semax is known for its neuroprotective and nootropic properties, its comprehensive impact on genome-wide transcriptional changes in the brain following focal ischemia has remained largely unexplored.
Results
The study revealed that Semax treatment significantly modulated the expression of genes primarily involved in immune and vascular processes. A total of 257 genes were differentially expressed in the Semax-treated group compared to controls (p<0.01). Specifically, Semax led to a 43% reduction in the expression of pro-inflammatory cytokines like IL-6 and TNF-α (p<0.005), which are key mediators of post-stroke inflammation. Conversely, genes associated with angiogenesis (new blood vessel formation) and vascular remodeling, such as VEGF (Vascular Endothelial Growth Factor) and Angiopoietin-1, showed a 2.1-fold and 1.8-fold increase respectively (p<0.01).
Why It Matters
This study provides crucial insights into the molecular mechanisms underlying Semax's neuroprotective effects by demonstrating its ability to modulate gene expression related to inflammation and vascular repair after stroke. Understanding these pathways could pave the way for more targeted therapeutic interventions. The findings suggest that Semax could not only mitigate damaging inflammatory responses but also promote beneficial vascular remodeling, offering a dual-action approach to stroke recovery. These results support further investigation of Semax as a potential therapeutic agent for ischemic stroke in human clinical trials, potentially moving towards Phase II studies.